KEY POINTS
  • Eli Lilly said its highly popular drug used for weight loss and diabetes, tirzepatide, showed promise as a treatment for fatty liver disease in a midstage trial. 
  • The results add to a long list of potential health benefits of the treatment besides helping patients shed pounds and regulate blood sugar under the drug's brand names, Zepbound and Mounjaro. 
  • The pharmaceutical giant said in its fourth-quarter earnings release that tirzepatide succeeded in a phase two trial as a treatment for a serious form of liver disease called MASH. 

In this article

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. 

Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial

The initial study results add to a long list of potential health benefits of the treatment, known as tirzepatide, besides helping patients shed significant pounds and regulate blood sugar under the drug's brand names, Zepbound and Mounjaro, respectively. Those additional benefits could potentially expand the limited insurance coverage for weight loss drugs, most of which cost close to $1,000 per month. 

In this article